Meningitis pipeline therapeutics constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities/Institutes.
Meningitis - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening. Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis.
Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market.
Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximately 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status.
Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If none of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely. Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby's head) may be visible.
Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis. The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects.
- Adenium Biotech ApS
- Amplyx Pharmaceuticals, Inc.
- Chiesi Farmaceutici SpA
- ContraFect Corporation
- Genticel S.A.
- LG Life Science LTD.
- Matinas BioPharma Holdings, Inc.
- Sanofi Pasteur SA
- Viamet Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/9lg8v5/meningitis